{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:50:09Z","timestamp":1758124209079},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"MRC","doi-asserted-by":"publisher","award":["MR\/K000608\/1"],"award-info":[{"award-number":["MR\/K000608\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.expneurol.2014.09.003","type":"journal-article","created":{"date-parts":[[2014,9,10]],"date-time":"2014-09-10T11:17:56Z","timestamp":1410347876000},"page":"812-815","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Repurposing of sodium channel antagonists as potential new anti-myotonic drugs"],"prefix":"10.1016","volume":"261","author":[{"given":"E.","family":"Matthews","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.G.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2014.09.003_bb0005","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0014-4886(85)90228-6","article-title":"Efficacy of phenytoin, procainamide, and tocainide in murine genetic myotonia","volume":"87","author":"Aichele","year":"1985","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0010","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1212\/01.wnl.0000257825.29703.e8","article-title":"Efficacy of propafenone in paramyotonia congenita","volume":"68","author":"Alfonsi","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2014.09.003_bb0015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF00316381","article-title":"Clinical and electrophysiological observations in patients with myotonic muscle disease and the therapeutic effect of N-propyl-ajmalin","volume":"210","author":"Birnberger","year":"1975","journal-title":"J. Neurol."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0020","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/brain\/62.4.341","article-title":"Congenital myotonia in the goat","volume":"62","author":"Brown","year":"1939","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2014.09.003_bb0025","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1113\/jphysiol.1969.sp008930","article-title":"Cable properties of external intercostal muscle fibres from myotonic and nonmyotonic goats","volume":"204","author":"Bryant","year":"1969","journal-title":"J. Physiol."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0030","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1542\/peds.2012-3065","article-title":"Diagnosis and outcome of SCN4A-related severe neonatal episodic laryngospasm (SNEL): 2 new cases","volume":"132","author":"Caietta","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.expneurol.2014.09.003_bb0035","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1038\/ncomms3044","article-title":"Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules","volume":"4","author":"Childs-Disney","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0040","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.bpj.2012.11.3830","article-title":"Combined modifications of mexiletine pharmacophores for new lead blockers of Na(v)1.4 channels","volume":"104","author":"De","year":"2013","journal-title":"Biophys. J."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0045","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.nmd.2004.04.006","article-title":"New potent mexiletine and tocainide analogues evaluated in vivo and in vitro as antimyotonic agents on the myotonic ADR mouse","volume":"14","author":"De","year":"2004","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0050","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.expneurol.2014.02.023","article-title":"Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs","volume":"255","author":"Desaphy","year":"2014","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0055","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1212\/WNL.57.10.1849","article-title":"Gating of myotonic Na channel mutants defines the response to mexiletine and a potent derivative","volume":"57","author":"Desaphy","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2014.09.003_bb0060","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00228-012-1414-3","article-title":"Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy","volume":"69","author":"Desaphy","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0065","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1177\/106002808802200209","article-title":"Tocainide: a severe adverse reaction","volume":"22","author":"Dunn","year":"1988","journal-title":"Drug Intell. Clin. Pharm."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0070","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/mus.20585","article-title":"Acetazolamide acts directly on the human skeletal muscle chloride channel","volume":"34","author":"Eguchi","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.expneurol.2014.09.003_bb0075","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.nmd.2006.01.015","article-title":"A new case of autosomal dominant myotonia associated with the V1589M missense mutation in the muscle sodium channel gene and its phenotypic classification","volume":"16","author":"Ferriby","year":"2006","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0080","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/jnnp.45.5.461","article-title":"A comparative study of disopyramide and procainamide in the treatment of myotonia in myotonic dystrophy","volume":"45","author":"Finlay","year":"1982","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.expneurol.2014.09.003_bb0085","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s004240050699","article-title":"Effects of temperature and mexiletine on the F1473S Na+ channel mutation causing paramyotonia congenita","volume":"436","author":"Fleischhauer","year":"1998","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0090","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00002060-198910000-00003","article-title":"A pilot controlled study of the use of imipramine to reduce myotonia","volume":"68","author":"Gascon","year":"1989","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0095","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/ng0493-305","article-title":"Molecular basis of Thomsen's disease (autosomal dominant myotonia congenita)","volume":"3","author":"George","year":"1993","journal-title":"Nat. Genet."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0100","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/brain\/78.1.81","article-title":"Procaine amide in the treatment of myotonia","volume":"78","author":"Geschwind","year":"1955","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2014.09.003_bb0105","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/jnnp.50.2.199","article-title":"Nifedipine in the treatment of myotonia in myotonic dystrophy","volume":"50","author":"Grant","year":"1987","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.expneurol.2014.09.003_bb0110","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/ana.410030614","article-title":"Effects of acetazolamide on myotonia","volume":"3","author":"Griggs","year":"1978","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0115","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S1471-4892(01)00050-9","article-title":"Human muscle voltage-gated ion channels and hereditary disease","volume":"1","author":"Jurkat-Rott","year":"2001","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0120","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF00204932","article-title":"Linkage data suggesting allelic heterogeneity for paramyotonia congenita and hyperkalemic periodic paralysis on chromosome 17","volume":"88","author":"Koch","year":"1991","journal-title":"Hum. Genet."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0125","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.1379744","article-title":"The skeletal muscle chloride channel in dominant and recessive human myotonia","volume":"257","author":"Koch","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.expneurol.2014.09.003_bb0130","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/mus.880100414","article-title":"Adynamia episodica hereditaria with myotonia: a non-inactivating sodium current and the effect of extracellular pH","volume":"10","author":"Lehmann-Horn","year":"1987","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.expneurol.2014.09.003_bb0135","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/mus.880040508","article-title":"Membrane defects in paramyotonia congenita with and without myotonia in a warm environment","volume":"4","author":"Lehmann-Horn","year":"1981","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.expneurol.2014.09.003_bb0140","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/brain\/82.1.81","article-title":"The treatment of myotonia: a controlled clinical trial","volume":"82","author":"Leyburn","year":"1959","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2014.09.003_bb0145","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1172\/JCI106703","article-title":"Cable parameters, sodium, potassium, chloride, and water content, and potassium efflux in isolated external intercostal muscle of normal volunteers and patients with myotonia congenita","volume":"50","author":"Lipicky","year":"1971","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0150","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1212\/WNL.0b013e3181dc1a3a","article-title":"Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1","volume":"74","author":"Logigian","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2014.09.003_bb0155","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.pediatrneurol.2010.01.014","article-title":"Novel CLCN1 mutation in carbamazepine-responsive myotonia congenita","volume":"42","author":"Lyons","year":"2010","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0160","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1097-2765(02)00563-4","article-title":"Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy","volume":"10","author":"Mankodi","year":"2002","journal-title":"Mol. Cell"},{"key":"10.1016\/j.expneurol.2014.09.003_bb0165","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1378\/chest.94.2.427","article-title":"Tocainide-associated neutropenia and lupus-like syndrome","volume":"94","author":"Oliphant","year":"1988","journal-title":"Chest"},{"key":"10.1016\/j.expneurol.2014.09.003_bb0170","first-page":"851","article-title":"Paramyotonia congenita and hyperkalemic periodic paralysis map to the same sodium-channel gene locus","volume":"49","author":"Ptacek","year":"1991","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0175","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1136\/jnnp.43.3.268","article-title":"Successuful treatment of paramyotonia congenita (Eulenburg): muscle stiffness and weakness prevented by tocainide","volume":"43","author":"Ricker","year":"1980","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.expneurol.2014.09.003_bb0180","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1172\/JCI200216481","article-title":"Functional repair of a mutant chloride channel using a trans-splicing ribozyme","volume":"110","author":"Rogers","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0185","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/ana.410420520","article-title":"A novel muscle sodium channel mutation causes painful congenital myotonia","volume":"42","author":"Rosenfeld","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0190","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/BF00313157","article-title":"Improved therapy of myotonia with the lidocaine derivative tocainide","volume":"222","author":"Rudel","year":"1980","journal-title":"J. Neurol."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0195","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1001\/jama.2012.12607","article-title":"Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial","volume":"308","author":"Statland","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.expneurol.2014.09.003_bb0200","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/ana.410190515","article-title":"Successful treatment with tocainide of recessive generalized congenital myotonia","volume":"19","author":"Streib","year":"1986","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0205","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/mus.880100209","article-title":"Paramyotonia congenita: successful treatment with tocainide. Clinical and electrophysiologic findings in seven patients","volume":"10","author":"Streib","year":"1987","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.expneurol.2014.09.003_bb0210","first-page":"CD004762","article-title":"Drug treatment for myotonia","author":"Trip","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0215","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1212\/WNL.37.3.488","article-title":"Acetazolamide-responsive myotonia congenita","volume":"37","author":"Trudell","year":"1987","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2014.09.003_bb0220","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/0002-8703(85)90373-4","article-title":"Tocainide associated agranulocytosis","volume":"109","author":"Volosin","year":"1985","journal-title":"Am. Heart J."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0225","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0960-8966(99)00060-7","article-title":"Different effects of mexiletine on two mutant sodium channels causing paramyotonia congenita and hyperkalemic periodic paralysis","volume":"10","author":"Weckbecker","year":"2000","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0230","first-page":"3952","article-title":"Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy","volume":"117","author":"Wheeler","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.expneurol.2014.09.003_bb0235","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/archneurpsyc.1936.02260080154011","article-title":"Quinine: an effective form of treatment for myotonia","volume":"36","author":"Wolf","year":"1936","journal-title":"Arch. Neurol. Psychiatr."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488614002866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488614002866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T21:17:47Z","timestamp":1565817467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488614002866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":47,"alternative-id":["S0014488614002866"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2014.09.003","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing of sodium channel antagonists as potential new anti-myotonic drugs","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2014.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}